Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease

General Inclusion Criteria: * Age ≥ 18 years; * Subjects (or legal guardians) understand the testing requirements and procedures, and provide written informed consent; * Subjects could undergo percutaneous coronary intervention (PCI); * Subjects have symptomatic coronary artery disease or have confirmed asymptomatic ischemia; * Subjects are eligible candidates for coronary artery bypass graft surgery (CABG); * Left ventricular ejection fraction (LVEF) within 60 days ≥ 30%; * Subjects were willing to accept the trial plan calls for all subsequent evaluations; * Subjects can endure 6 months dual anti-platelet therapy, and met one or more criteria as the following: 1.Age ≥ 75years; 2.Subjects with hemoglobin\<10g/dL, or subjects received transfusion therapy 4 weeks ago; 3.Subjects with renal insufficiency (eGFR \< 60 ml / min); 4. Subjects with HAS-BLED score ≥3.0; 5.Femal patients with acute cononary syndrome; 6.BMI \< 18.5 Kg/M2; 7.Subjects with congestive heart failure and with LVEF30%-50%; 8.Subjects had a history of hospitalization due to bleeding; 9.Subjects with thrombocytopenia (platelet \< 100,000 / mm3); 10.Subjects had a histroy of intracranial hemorrhage; 11.Subjects had a histroy of intracranial ischemia stroke in 6 months; 12.Subjects plan to receive non-steroidal anti-inflammatory or steroid treatment for more than 30 days after the baseline PCI; 14.Subjects were expected to receive additional treatment after PCI and cannot undergo long-term DAPT therapy; 15.Subjects had a history of stomach ulcers or active ulcers. Angiographic Inclusion Criteria * Target lesions must be new and have a visually estimated reference diameter ≥2.25 mm and ≤4.0 mm in autologous coronary artery; * Target lesions must be moderate-severe calcification; * No limitations in target lesion length and number, and the number of implanted stents is less than 4; * ALL target lesion must be able to successfully expand and implant Firehawk™ stent. Clinical Exclusion Criteria: * Subjects recently suffer from MI (within 4 week) and ECG changes/clinical symptoms consistent with AMI, or accompanied with increased cardiac biomarkers (CK-MB, CK, TNT or TNI) and at least one of the following : 1. CK-MB\> 3ULN, regardless of the value of total CK; 2. If CK-MB or CK was not detected, but cTN\> 1ULN, and at least one of the following: 1. Ischemic symptoms and ECG changes of new ischemia; 2. Development of pathologic Q waves in the ECG; 3. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. * Subject had Re-MI before randomized; * Subject with hemodynamic instability (Killip class IV); * Subjects were detected ventricular aneurysm greater than 3.0\*2.0cm or intraventricular thrombosis by cardiac ultrasonography in 30 days; * Subjects with Life-threatening arrhythmias; * Subjects were expected to receive oral anticoagulation therapy after the baseline PCI; * Subjects cannot endure dual anti-platelet therapy for 1 month; * Subjects with mechanical complications after myocardial infarction; * Subjects had an organ transplant or are waiting for an organ transplant; * Subjects are receiving chemotherapy or will receive a chemotherapy within 30 days after PCI; * Subjects with abnormal counts of white blood cell (WBC); * Subjects with verified or suspected acute liver disease, including lab results of acute liver disease; * Subjects had permanent neurological diseases in the past 6 months; * Subjects had any PCI (such as balloon angioplasty, stent, cutting balloon) treatment in target vessels within 12 months prior to baseline; * Non-target vessel had been implanted non-research stent 5 months ago before the baselin PCI. * Subjects plan to undergo PCI or CABG within 1 year after the baseline PCI; * Subjects have any coronary endovascular brachytherapy treatment previously; * Subjects associated with drugs allergy (such as sirolimus, or structure-related compounds fluorinated polymers, thiophenepyridine or aspirin); * Subjects are suffering from other serious illness (such as cancer, congestive heart failure), which may cause drop in life expectancy to less than 12 months; * Subjects are currently abusing drugs (such as alcohol, cocaine, heroin, etc); * Subject plan to undergo any operations that may lead to confuse with the programme; * Subjects were participating in another study of drug or medical device which did not meet its primary endpoint; * Subjects plan to pregnant within 12 months after baseline; * Subjects are pregnant or breastfeeding women. Angiographic Exclusion Criteria (visual estimate): * Target lesions with the following criteria: left main, saphenous vein grafts or arterial grafts, via saphenous vein grafts or arterial graft, more than 4 stents have been implanted and in-stent sestenosis; * Subjects with unprotected left main coronary artery disease (diameter stenosis \>50%); * Subjects have a protected left main coronary artery disease (diameter stenosis\> 50% and left coronary artery bypass surgery), as well as target lesions located in the LAD and LCX; * Subjects with other lesions of clinical significance, may be need intervention within 12 months after baseline.